1. Enterprise Software License & Master Contracting Framework
These Terms of Service & Master Software License Agreement ("Agreement") constitute the legally binding contract between QA Stack Technologies ("QA Stack", "Licensor", "We", "Us") and the subscribing enterprise or pharmaceutical manufacturer ("Customer", "Licensee", "You").
Sovereign Enterprise Terms: QA Stack maintains its own dedicated, life-sciences-specific legal and commercial terms inspired by global enterprise standards, safeguarding both parties across all procurement and deployment methods:
- Microsoft Commercial Marketplace Procurement: When Customer procures QA Stack via the Microsoft Commercial Marketplace or Azure Portal (including 100% MACC commitment drawdown), Microsoft acts as the commercial billing facilitator, while this QA Stack Master Enterprise Agreement directly governs the software license, GxP performance SLA, regulatory defensibility, and data ownership between QA Stack Technologies and Customer.
- Direct Enterprise Engagements & Cleanroom Buyouts: When Customer licenses QA Stack via an authorized direct Order Form, Master Subscription Agreement, or Perpetual On-Premise Air-Gapped Buyout, this Agreement constitutes the entire operative contract governing deployment, validation protocols, and technical support.
2. Regulated Life Sciences Software & Shared Responsibility Model (GxP Disclaimer)
QA Stack is categorized as a GAMP 5 Category 4 Configurable Software Application. It provides pre-engineered software controls designed to enable Customer compliance with US FDA 21 CFR Part 11, EU Annex 11, WHO-GMP, and CDSCO Schedule M (including cryptographic ALCOA+ audit trails, electronic signature manifests, and automated training gates).
Customer Regulatory Responsibility: The Customer explicitly acknowledges that QA Stack is a software vendor and not a drug manufacturer, licensed testing laboratory, or regulatory agency. Under FDA and global GMP regulations, the Customer remains solely responsible for:
- Establishing, reviewing, and approving plant-specific Standard Operating Procedures (SOPs).
- Managing user authentication policies, user access de-provisioning, and credential confidentiality within Customer's Microsoft Entra ID tenant.
- Executing formal Computerized System Validation (IQ/OQ/PQ) within Customer's specific operating environment prior to commercial drug batch release.
- Final pharmaceutical batch release determinations and regulatory audit submissions.
QA Stack provides pre-packaged IQ/OQ/PQ validation test execution protocols to accelerate Customer qualification, but formal operational sign-off resides exclusively with Customer's Quality Unit.
3. Plant-Wide Licensing & Microsoft MACC Drawdown
QA Stack licenses software on a Plant-Wide / Facility-Tier model without per-user seat scaling penalties. Authorized users within the licensed physical facility or designated business unit may access the subscribed modules (DMS, TMS, QMS, SQM).
All Marketplace transactions qualify for 100% Microsoft Azure Consumption Commitment (MACC) drawdown, allowing eligible enterprise customers to deduct licensing costs directly from pre-committed Microsoft Azure cloud budgets.
4. Electronic Signatures, Data Ownership & Audit Integrity
Customer Data Ownership: The Customer retains 100% exclusive ownership of all documents, master formulas, deviation logs, CAPA records, training matrices, and metadata stored within QA Stack. QA Stack claims zero intellectual property or ownership rights over Customer manufacturing records.
Legal Equivalence of Electronic Signatures: Customer agrees that electronic signatures executed within QA Stack via Microsoft Entra ID dual-credential verification satisfy the requirements of 21 CFR §11.50 and Sections 4 and 5 of the Indian Information Technology Act, 2000, possessing the exact legal validity and enforceability of handwritten pen-and-ink signatures.
5. Service Level Agreement (SLA) & High Availability
For Microsoft Azure single-tenant cloud deployments, QA Stack commits to a 99.95% GxP Application Availability SLA. Critical Severity 1 incidents (system down affecting manufacturing line operations) receive engineering response within thirty (30) minutes.
In air-gapped on-premise cleanroom deployments, infrastructure uptime remains the operational responsibility of Customer's IT infrastructure team, with software patches and L3 technical support provided by QA Stack.
6. Limitation of Liability & Comprehensive Defense
CONSEQUENTIAL DAMAGES WAIVER: TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, IN NO EVENT SHALL QA STACK TECHNOLOGIES, ITS DIRECTORS, EMPLOYEES, PARTNERS, OR LICENSORS BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE, COVER, OR CONSEQUENTIAL DAMAGES WHATSOEVER (INCLUDING, WITHOUT LIMITATION, DAMAGES FOR LOSS OF REVENUES, BATCH CONTAMINATION, DRUG PRODUCT RECALLS, REGULATORY FINES, FDA FORM 483 OBSERVATIONS, WARNING LETTERS, LOSS OF GOODWILL, OR BUSINESS INTERRUPTION), REGARDLESS OF THE THEORY OF LIABILITY (CONTRACT, TORT, STRICT LIABILITY, OR OTHERWISE).
AGGREGATE MONETARY CAP: IN NO EVENT SHALL THE TOTAL AGGREGATE LIABILITY OF QA STACK TECHNOLOGIES ARISING OUT OF OR RELATED TO THIS AGREEMENT EXCEED THE TOTAL AMOUNT ACTUALLY PAID BY CUSTOMER TO QA STACK IN THE TWELVE (12) MONTHS IMMEDIATELY PRECEDING THE EVENT GIVING RISE TO THE CLAIM.
7. Mutual Indemnification
IP Infringement Defense: QA Stack will defend Customer against any third-party claim alleging that the unadulterated QA Stack platform directly infringes any valid patent, copyright, or trademark, and will indemnify Customer against damages finally awarded by a court of competent jurisdiction.
Customer Indemnification: Customer will defend and indemnify QA Stack against any third-party claims, regulatory enforcement actions, or losses arising from Customer's pharmaceutical manufacturing operations, failure to execute SOPs, adulteration or misbranding of drug products, or gross negligence.
8. Governing Law, Dispute Resolution & Exclusive Jurisdiction
This Agreement and any dispute or controversy arising out of or in connection with it shall be governed by and construed in accordance with the substantive laws of the Republic of India, without giving effect to any choice of law or conflict of law principles.
Binding Arbitration: Any dispute, controversy, or claim arising out of or relating to this Agreement shall be referred to and finally resolved by binding arbitration conducted under the provisions of the Arbitration and Conciliation Act, 1996. The seat and venue of arbitration shall be Chandigarh, India. The language of arbitration shall be English.
Exclusive Jurisdiction: Subject to the arbitration clause above, the competent courts situated in Chandigarh, India shall have sole and exclusive territorial and subject-matter jurisdiction over any legal proceedings arising under or related to this Agreement.